Peptide side effects: what to expect in general
Reviewed 15 sourcesPublished by PepVault
Peptide side effects in general: the injection-site reaction most share, then what GLP-1s, growth-hormone peptides and melanocortins add, at label rates.

- Last reviewed
- Sources
- 15
- Questions
- 8
- Compounds
- 14
The short answer
Most peptides injected under the skin share one side effect: a red, itchy or sore spot where the needle went in. Beyond that, the family decides. GLP-1s bring nausea and other stomach effects (44% on Wegovy against 16% on placebo), growth-hormone peptides bring water retention, tingling and hunger, and melanocortins bring nausea, flushing and darker skin. The common ones mostly ease with time.
Evidence: FDA labels and their placebo-controlled trials for the GLP-1s, tesamorelin and the approved melanocortins; smaller placebo-controlled trials for MK-677 and ipamorelin; a mouse and human-cell study for the histamine mechanism; no controlled human safety data for BPC-157 or TB-500.


Why does the injection spot get red and itchy?
Three things add up. The first is the needle and the liquid itself: a small wound and a small pocket of fluid in the fat under the skin. Some soreness is expected after any shot14.
The second is histamine, the itch-and-swell chemical of allergy. Mast cells, immune cells that sit in the skin, can release it without any allergy at all when a positively charged molecule touches a receptor on their surface called MRGPRX2. Many peptide drugs carry that charge. A 2015 study in Nature found that most classes of approved peptide drugs linked to injection-site reactions switched this receptor on in lab-grown cells, including human mast cells, and that mice bred without their version of the receptor got no swelling where icatibant was injected8. That explains a red, itchy flare at the spot that is not a true allergy.
The third is the immune system learning the peptide. Some people make antibodies to it, a response called immunogenicity. On Zepbound, injection-site reactions came in 11.3% of people who made antibodies to tirzepatide, against 1% of those who did not; the antibodies did not change how well the drug worked2.
Which side effects come with each peptide family?
Past the injection spot, a peptide's side effects follow the receptor it acts on. Each row gives the family's typical effects with the drug's rate against placebo, from the source with the best evidence for that family:
| Family | Example | Typical side effects (drug against placebo) | Evidence |
|---|---|---|---|
| GLP-1 and incretin drugs | Semaglutide (Wegovy), tirzepatide (Zepbound) | Nausea 44% against 16% on Wegovy 2.4 mg1; nausea 25% to 29% against 8% on Zepbound2; diarrhea, vomiting, constipation | FDA labels, large placebo-controlled trials |
| Growth-hormone-releasing hormone analogues | Tesamorelin (Egrifta SV) | Joint pain 13% against 11%; swollen hands, legs or feet 6% against 2%; muscle aches 6% against 2%; tingling 5% against 2%3 | FDA label, 26-week placebo-controlled trials |
| Ghrelin mimetics | MK-677 (ibutamoren), ipamorelin | MK-677: more appetite, mild leg swelling, muscle pain9; ipamorelin after bowel surgery: any health event after surgery, drug-related or not, in 87.5% against 94.8% on placebo10 | Placebo-controlled trials, no approved label |
| Melanocortins | Bremelanotide (Vyleesi), setmelanotide (Imcivree) | Vyleesi: nausea 40% against 1.3%, flushing 20.3% against 0.3%, headache 11.3% against 1.9%4; Imcivree: darker skin 67% against 0% over 14 weeks5 | FDA labels; small pilot studies for melanotan II1115 |
| Repair peptides | BPC-157, TB-500 | No trial has counted them. User reports only, not trial rates: site irritation, nausea, tiredness | User reports only; FDA has no or only limited safety information on BPC-157 and no human exposure data on TB-50013 |
Rates from different trials are not directly comparable: the people, doses and trial lengths differ. Read each number against its own placebo column, not against the next row.
What do GLP-1 side effects look like?
Mostly stomach effects, mostly early. GLP-1 drugs slow how fast the stomach empties, and in Zepbound's weight trials 56% of people on each dose had at least one stomach side effect, against 30% on placebo. The label adds that most nausea, vomiting and diarrhea came while the dose was being raised and decreased over time2. Retatrutide, still in trials, shows the same shape: in its phase 2 trial the stomach effects rose with the dose, were mostly mild to moderate, and were partly eased by a lower starting dose12.
Both labels also carry a boxed warning: in rodents these drugs caused thyroid C-cell tumours, and they are not for anyone with a personal or family history of medullary thyroid cancer or MEN 212. They also warn of pancreatitis: severe belly pain that will not go away, sometimes spreading to the back, with or without vomiting12.
Fluids matter on these drugs. The labels report kidney injury after approval, mostly in people who were dehydrated from vomiting or diarrhea2. The rates at every dose, the timing week by week and the eating habits that help are in our guides to Ozempic and Wegovy side effects, Mounjaro and Zepbound side effects, and retatrutide side effects.
What do growth-hormone peptides do to water, hands and hunger?
Water retention leads, because growth hormone itself holds fluid in the tissues. The tesamorelin label ties its fluid retention to the growth hormone the drug releases: swollen hands and feet, joint pain and, less often, carpal tunnel syndrome, the tingling or numb fingers that come when a swollen wrist presses on a nerve (1% against 0%). The label says these are transient or go away when the drug stops3. The same label adds a blood-sugar effect: 5% on tesamorelin developed diabetes-range HbA1c, against 1% on placebo3.
Ghrelin mimetics add hunger, because ghrelin is the body's hunger hormone. In a two-year trial in 65 adults aged 60 to 81, MK-677 taken by mouth each day raised appetite in a way that subsided within a few months, with transient, mild leg swelling and muscle pain. Fasting blood sugar rose by an average of 5 mg/dL and insulin sensitivity fell9. Ipamorelin's one placebo-controlled trial, given into a vein for up to 7 days after bowel surgery, found it well tolerated10.
What do melanocortin peptides do to skin and stomach?
Melanocortin receptors, a family of receptors that set skin pigment, appetite and sexual arousal, explain all three effects these peptides share: nausea, flushing and darker skin. Bremelanotide (PT-141) shows the timing best. Its nausea started within an hour of the dose at the median and lasted about two hours. It came in 21% of people after the first dose and about 3% after later doses; 13% took a medicine for it and 8% stopped4. Blood pressure also rises briefly, by up to 6 mmHg systolic at 2 to 4 hours, and is usually back within 12 hours4.
Darker skin depends on how often the peptide is given. On bremelanotide used up to 8 times a month, focal darkening of the face, gums or breasts came in 1%, against none on placebo; in a study of daily use for 8 days it came in 38%, more often in people with darker skin, and fading was not confirmed in everyone after stopping4. On daily setmelanotide, skin darkening came in most people, and its label says it reverses when the drug stops5. The tanning implant afamelanotide darkened skin in 4%, against 0%6.
Melanotan II, the injected tanning peptide with no approval, has only small human studies. The first, a 1996 pilot in three men, found mild nausea at most doses, a yawning and stretching spell, spontaneous erections for 1 to 5 hours after a dose, and, in two of the three, a darker face and upper body a week after the last shot11. A placebo-controlled trial in 10 men found the same short-lived nausea and yawning, none of which needed treatment15. The compound's differences from melanotan I are in our melanotan guide.
What about BPC-157, TB-500 and other research peptides?
Here the honest answer is that nobody has counted. FDA's list of compounding substances with possible safety risks (current as of April 2026) says it has no, or only limited, safety information on BPC-157 for the routes proposed, and that it has identified no human exposure data for TB-500; for both it names a possible risk of immune reactions to compounded versions13. That is a statement about missing data, not a finding of harm. What exists is what users describe.
Commonly reported: on BPC-157, mild site irritation, occasional nausea, light-headedness and vivid dreams; on TB-500, tiredness or a lethargic day after a dose; on ipamorelin and CJC-1295, a warm flush minutes after the shot, puffy fingers and a tingle in the hands; on GHRP-6, strong hunger soon after the shot.
These are user reports, not trial results, and no placebo group sits beside them.
What helps with the common side effects?
Most of the help is in the labels themselves. In the order a week on a peptide runs:
- Give each shot a different spot, as the tesamorelin and tirzepatide labels advise, and press a gauze on any drop of blood rather than rubbing it23.
- Let the slow dose climb do its work: the GLP-1 labels start low and step up because most stomach effects come during the climb and fade after it2.
- Drink through the day, and more on any day with vomiting or diarrhea, since dehydration is what strains the kidneys2.
- Know that a first-dose effect may not repeat: in the bremelanotide trials, nausea came after the first dose in 21% and after later doses in about 3%4.
- Expect fluid effects from growth-hormone peptides to pass: the tesamorelin label calls them transient or gone once the drug stops3.
- On a melanocortin, have your skin and moles looked at before you start and regularly after; setmelanotide's label asks for a full-body skin exam before and during treatment5.
- Bring a dated record of what you felt to your prescriber before changing a dose, which is their decision.
PepVault's side-effect log records each symptom with its compound, a severity from minimal to very severe, the date and a note, and offers that compound's common symptoms as one-tap choices. Log it in PepVault
When to get help Get medical help promptly for swelling of the face, lips, tongue or throat, trouble breathing, severe belly pain that will not go away, sometimes spreading to the back (a sign of pancreatitis on the GLP-1 labels), or redness at a site that spreads with red streaks or a fever214.
Sources
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets: prescribing information, section 6.1. DailyMed, SPL version 19, updated June 18, 2026 (published June 30, 2026). dailymed.nlm.nih.gov
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: prescribing information, sections 2, 5 and 6.1, and Medication Guide. DailyMed, SPL version 40, updated August 28, 2026 (published September 2, 2026). dailymed.nlm.nih.gov
- Theratechnologies. EGRIFTA SV (tesamorelin) for injection: prescribing information, sections 5.3, 5.6 and 6.1 (Table 1). DailyMed, SPL version 9, updated July 29, 2026 (published July 31, 2026). dailymed.nlm.nih.gov
- Cosette Pharmaceuticals. VYLEESI (bremelanotide injection): prescribing information, sections 5.1 to 5.3 and 6.1 (Table 1). DailyMed, SPL version 2, updated November 5, 2026 (published November 9, 2026). dailymed.nlm.nih.gov
- Rhythm Pharmaceuticals. IMCIVREE (setmelanotide) injection: prescribing information, sections 5.4 and 6.1. DailyMed, SPL version 14, updated April 1, 2026 (published April 2, 2026). dailymed.nlm.nih.gov
- Clinuvel. SCENESSE (afamelanotide) implant: prescribing information, section 6.1. DailyMed, SPL version 11, updated May 11, 2026 (published May 13, 2026). dailymed.nlm.nih.gov
- Takeda. FIRAZYR (icatibant) injection: prescribing information, section 6. DailyMed, SPL version 19, updated July 7, 2025 (published July 17, 2025). dailymed.nlm.nih.gov
- McNeil BD, Pundir P, Meeker S et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015. PubMed 25517090
- Nass R, Pezzoli SS, Oliveri MC et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008. PubMed 18981485
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014. PubMed 25331030
- Dorr RT, Lines R, Levine N et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996. PubMed 8637402
- Jastreboff AM, Kaplan LM, Frías JP et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. PubMed 37366315
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov
- MedlinePlus (US National Library of Medicine). Subcutaneous (SQ) injections. Medical Encyclopedia, reviewed October 19, 2025. medlineplus.gov
- Wessells H, Fuciarelli K, Hansen J et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998. PubMed 9679884
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.
